Researchers have found that a new inhaled treatment called LAM-001 may significantly improve lung function in adults with pulmonary hypertension associated with interstitial lung disease (PH-ILD). In a recent study, patients experienced a notable increase in their six-minute walk distance (6MWD) by an average of 67.4 meters after 24 weeks of treatment. Additionally, the treatment led to a reduction in pulmonary vascular resistance (PVR) by 33.9%, indicating improved blood flow in the lungs.

This discovery is particularly important for people living with PH-ILD, a serious condition that limits daily activities and poses a high risk of worsening health. The improvements in exercise capacity and lung function could translate to better overall quality of life for those affected. The study involved 10 adult patients who were still experiencing symptoms despite receiving standard treatments, suggesting that LAM-001 may offer a new option for those who have not found relief with existing therapies.

The evidence comes from a Phase 2a clinical trial, which is an early-stage study designed to test the safety and effectiveness of a treatment. While the results are promising, further research is needed to confirm these benefits in larger groups of patients. A Phase 2b trial is set to begin in mid-2026, with results expected in early 2028. This means that while LAM-001 shows potential, it is not yet widely available or proven as a standard treatment.

For those interested in lung health, staying informed about upcoming trials and discussing new treatment options with healthcare providers could be beneficial, especially for individuals dealing with pulmonary hypertension or related conditions.

Source: globenewswire.com